AstraZeneca (AZN) and partner Shionogi (SGIOF.PK) have received a boost after Actavis (ACT) unit Watson Laboratories and Egis agreed to drop their attempts to introduce generic versions of AstraZeneca's blockbuster cholesterol drug Crestor until May 2016. The settlement comes after a court upheld the patent on the treatment in December.
Shionogi-ViiV Healthcare, a JV involving GSK, Pfizer (PFE) and Shionogi, says a Phase III trial of its dolutegravir HIV treatment suggests it might be more effective than Gilead's (GILD) and Bristol-Myers Squibb's (BMY) Atripla drug. GSK shares +0.3% in London. (PR)